Cannabis Science Expands Cancer Portfolio to Include Leukemia Treatment Research Utilizing Cannabinoid-Based …

IRVINE, CA , Jan. 31, 2018 (GLOBE NEWSWIRE) — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that the Company’s research team is expanding the scope of its current cancer research to include Leukemia.

“As we gain increasing clarity of how cannabinoids work we will influence the development of drug delivery mechanisms, the use and dosage of appropriate cannabinoids, and the identification of target conditions,” stated Dr. Allen Herman, CBIS’ Chief Medical Officer. “Cannabis Science believes that cannabis extracts are critical instruments in cancer treatment and that we have

...read more at https://globenewswire.com/news-release/2018/01/31/1329593/0/en/Cannabis-Science-Expands-Cancer-Portfolio-to-Include-Leukemia-Treatment-Research-Utilizing-Cannabinoid-Based-Medicines.html

by